Critical care is a branch of medicine that involves the specialized treatment of patients with acute, life-threatening illness or injury. It is an area of persistent unmet need and significant consumption of healthcare resources. For example, critical care expense in the U.S. represents the equivalent of nearly one percent of its gross domestic product.
The partnership unites Philips’ strength in patient monitoring and the design and implementation of applications to help clinicians make more informed care decisions, and Immunetrics’ strengths in the dynamic modeling and simulation of complex biological systems.
Henk van Houten, senior vice president of Philips Research and head of its Healthcare Research program said, The management of the condition of critical care patients involves the monitoring and control of a multitude of parameters, a field in which Philips has a leading position. Yet, we see patient outcomes that are frequently unpredictable and sub-optimal. Through our collaboration with Immunetrics, a leader in computational modeling of pathophysiology and treatment, we will broaden our portfolio of research approaches directed to assessing infection risk and optimizing intervention, with the goal of improving the quality of care and reducing the mortality of critically ill patients.
Steven Chang, president and CEO of Immunetrics said, Immunetrics is excited to team with Philips Research and its significant technology resources with the goal of advancing patient care across the acute care setting.